Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.
复制标题
DOI:
10.1002/cpt.2149
复制
发表时间:
2021-10
影响因子:
6.7
通讯作者:
Skaar TC
中科院分区:
文献类型:
--
作者:
Crews KR;Monte AA;Huddart R;Caudle KE;Kharasch ED;Gaedigk A;Dunnenberger HM;Leeder JS;Callaghan JT;Samer CF;Klein TE;Haidar CE;Van Driest SL;Ruano G;Sangkuhl K;Cavallari LH;Müller DJ;Prows CA;Nagy M;Somogyi AA;Skaar TC
Opioids are mainly used to treat both acute and chronic pain. Several opioids are metabolized to some extent by CYP2D6 (codeine, tramadol, hydrocodone, oxycodone and methadone). Polymorphisms in CYP2D6 have been studied for an association with the clinical effect and safety of these drugs. Other genes which have been studied for their association with opioid clinical effect or adverse events include OPRM1 (mu receptor) and COMT (catechol-O-methyltransferase). This guideline updates and expands the 2014 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and codeine therapy and includes a summation of the evidence describing the impact of CYP2D6, OPRM1 and COMT on opioid analgesia and adverse events. We provide therapeutic recommendations for the use of CYP2D6 genotype results for prescribing codeine and tramadol and describe the limited and/or weak data for CYP2D6 and hydrocodone, oxycodone and methadone and for OPRM1 and COMT for clinical use.
登录
查看更多内容
影响因子:
2.8
作者:
Kirchheiner, J.;Schmidt, H.;Brockmoeller, J.
通讯作者:
Brockmoeller, J.
影响因子:
158.5
作者:
Gasche, Y;Daali, Y;Desmeules, J
通讯作者:
Desmeules, J
影响因子:
6.7
作者:
Crews, K. R.;Gaedigk, A.;Skaar, T. C.
通讯作者:
Skaar, T. C.
影响因子:
2.9
作者:
Andreassen, Trine Naalsund;Eftedal, Ingrid;Dale, Ola
通讯作者:
Dale, Ola
影响因子:
7.4
作者:
Loetsch, Joern;Rohrbacher, Maren;Geisslinger, Gerd
通讯作者:
Geisslinger, Gerd